行情

EVOK

EVOK

Evoke Pharma
NASDAQ

实时行情|Nasdaq Last Sale

1.480
+0.380
+34.55%
已收盘, 19:56 11/18 EST
开盘
1.150
昨收
1.100
最高
1.490
最低
1.100
成交量
185.58万
成交额
--
52周最高
3.260
52周最低
0.5001
市值
3,586.32万
市盈率(TTM)
-3.9806
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EVOK 新闻

  • 沪指低开高走 鲍威尔同特朗普及美财长会晤
  • 新浪财经.36分钟前
  • 泰国推“减塑”政策 商场超市等明年起不提供塑料袋
  • 中国新闻网.4小时前
  • 苹果“泰坦计划”又获新专利 可进行自动驾驶导航
  • 36氪.4小时前
  • 特朗普再次召见美联储主席讨论经济问题
  • 新华社.4小时前

更多

所属板块

制药
+0.06%
制药与医学研究
+0.13%

热门股票

名称
价格
涨跌幅

EVOK 简况

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
展开

Webull提供Evoke Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。